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Abstract
Apolipoprotein M (apoM) is a 26-kDa protein that is mainly associated with high-density lipoprotein
(HDL) in human plasma, with a small proportion present in triglyceride-rich lipoproteins (TGRLP)
and low-density lipoproteins (LDL). Human apoM gene is located in p21.31 on chromosome 6
(chromosome 17, in mouse). Human apoM cDNA (734 base pairs) encodes 188-amino acid
residue-long protein. It belongs to lipocalin protein superfamily. Human tissue expression array
study indicates that apoM is only expressed in liver and in kidney and small amounts are found in
fetal liver and kidney. In situ apoM mRNA hybridization demonstrates that apoM is exclusively
expressed in the hepatocytes and in the tubule epithelial cells in kidney. Expression of apoM could
be regulated by platelet activating factor (PAF), transforming growth factors (TGF), insulin-like
growth factor (IGF) and leptin in vivo and/or in vitro. It has been demonstrated that apoM expression
is dramatically decreased in apoA-I deficient mouse. Hepatocyte nuclear factor-1α (HNF-1α) is an
activator of apoM gene promoter. Deficiency of HNF-1α mouse shows lack of apoM expression.
Mutations in HNF-1α (MODY3) have reduced serum apoM levels. Expression of apoM is
significantly decreased in leptin deficient (ob/ob) mouse or leptin receptor deficient (db/db) mouse.
ApoM concentration in plasma is positively correlated to leptin level in obese subjects. These may
suggest that apoM is related to the initiation and progression of MODY3 and/or obesity.
Cloning and characterization of human apoM
Human apolipoprotein M (apoM) was found and initially
isolated from chylomicrons by Xu and Dahlbäck in 1999
[1]. When they performed SDS-PAGE for delipidated
human triglyceride-rich lipoprotein (TGRLP) and
sequenced protein bands ranging from 6–45 kDa, one of
sequences identified as the N-terminal sequence of MFH-
QIWAALLYFYGI. No homologous protein was identified
in public databases, but several human expressed
sequence tags (EST) were found similar to these N-termi-
nal amino acid sequence. Based on these sequences, full-
length cDNA of the novel protein was obtained with 188
amino acids [1]. Rabbit antibodies were raised against five
synthetic peptides based on the protein sequence. The
pooled antisera were used to analyze distribution of the
protein among various lipoprotein subclasses using West-
ern blotting. Under reducing conditions, a 26-kDa band
was particularly predominant in high density lipoprotein
(HDL) but was also observed in low density lipoprotein
(LDL) and TGRLP. A less pronounced band
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sponded in size to the non-glycosylated protein [1]. As
majority of the protein is associated with lipoprotein in
plasma, it fulfills the criteria for classification as an apoli-
poprotein. And this novel protein was named apolipopro-
tein M (apoM) [1] as the last previously identified
apolipoprotein was called apoL [2]. Gel filtration of
plasma showed that apoM was associated with HDL-sized
particles in wide-type and apoA-I deficient mice and with
HDL- and LDL-sized particles in LDL receptor-deficient
mice, whereas it was mainly found in VLDL (very low den-
sity lipoprotein)-sized particles in high-fat, high-choles-
terol-fed apoE deficient mice [3]. These data suggest that
apoM mainly associates with HDL in normal mice, but
also with the pathologically increased lipoprotein fraction
in genetically modified mice.
Gene location and amino acid sequence of apoM
The identified human apoM cDNA (734 base pairs)
encoded 188-amino acid residue-long protein. The 5'-
untranslated region was 33 nucleotides and the 3'-
untranslated region 120 nucleotides, not including the
poly (A) tail. Southern blot analysis of different species
gave positive signals in all mammalian genomes but not
in DNA from chicken and yeast [1]. Human apoM gene is
located in p21.31 on chromosome 6 (Fig. 1) (chromo-
some 17, in mouse). The genomic sequence of this region
was determined and the human apoM gene identified
(GenBank accession number AF118393). In human
genome, the apoM gene is surrounded by BAT4 and NG34
on one side and BAT3 on the other. Both mouse apoM
gene and its human counterpart are predicted to contain
6 exons enclosed in a 1.6-kb genomic region, which is
consistent with the results of Southern blotting. The calcu-
lated molecular mass of the protein was 21,256. There is
one potential site for N-linked glycosylation at Asn-135
(Asn-Glu-Thr), whereas Asn-148 (Asn-Arg-Ser-Pro) is less
likely to be glycosylated because Pro-151 follows Ser-150.
The amino acid sequences of human and mouse apoM are
79% identical (82%, human and rat apoM) (Fig. 2), and
just like human apoM the mouse sequence predicts the
presence of a signal anchor, as there is no predicted signal
peptidase cleavage site. The amino acid sequence of apoM
contained six cysteines, which may involve in the forma-
tion of three disulfide bridges.
Protein structure of apoM
Based on sensitive sequence searches, it is proposed that
apoM is related to the lipocalin protein superfamily (Fig.
2) [1]. Subsequently, Duan et al. [4], used computer pro-
tein modeling of two lipocalins, mouse major urinary
protein (MUP) and human retinol binding protein (RBP)
as initial templates to build apoM protein structure, which
demonstrated that apoM has the same structure of lipica-
lin protein superfamily. ApoM retains an uncleaved N-ter-
minal signal peptide that most likely anchors the
molecule into single layer lipids on HDL [4]. The major
phospholipids in HDL is phosphatidylcholine, which has
a positively charged choline group exposed to the solvent.
Two electronegative regions are striking in the apoM
model and are located around the N-terminus and the
opening of the binding pocket. In this three-dimensional
model, characterized by an eight-stranded anti-parallel β-
barrel, a segment including Asn-135 could adopt a closed
or open conformation. ApoM presents three disulfide
bridges, which would make it a member of the lipcalin
subgroup of proteins with three s-s bonds [4].
Tissue distribution and cellular expression of 
apoM
Northern blot analyses of multiple tissues (including
spleen, thymus, prostate, testis, ovary, small intestine,
colon, leukocytes, heart, brain, placenta, lung, liver, skel-
etal muscle, kidney, pancreas, stomach, thyroid, spinal
cord, lymph node, trachea, adrenal gland and bone mar-
row) showed that apoM was mainly expressed in kidney
and liver [1]. Furthermore, human tissue expression array
study indicated that apoM is only expressed in liver and in
kidney and small amounts were found in fetal liver and in
fetal kidney [5]. To elucidate whether and when apoM is
expressed, Zhang et al. investigated apoM expression
patterns during mouse and human embryogenesis [6].
ApoM gene location in chromosome 6Figure 1
ApoM gene location in chromosome 6. ApoM gene is located in chromosome 6 p21.31 http://bioinfo.weizmann.ac.il/cards-bin/
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7.5 to day 18.5. It was expressed at low levels at day 7.5,
increased significantly at day 9.7 and decreased at day
10.5, and then increased continually up to day 18.5.
ApoM-positive cells appeared mainly in liver of day 12
embryos as detected by in situ hybridization. In day-15
embryos, apoM was expressed in both liver and kidney.
During human embryogenesis, apoM was strongly
expressed in livers of 3–5 month-old human embryos and
continued to be strongly expressed throughout embryo-
genesis. In the kidney, apoM expression was highest in 5–
9 month-old embryos. There was some expression of
apoM in small intestine, particularly in later stages of
embryogenesis. In skeletal muscle, minute apoM expres-
sion was found in 3–5 months-old embryos, and some
apoM expression was found in stomach in earlier stages of
embryogenesis [6]. These finding suggest that apoM has
high organ specificity and strongly indicate that the phys-
iological function of apoM must be related with liver and
kidney. Both immunohistochemical staining and in situ
apoM mRNA hybridization demonstrated that apoM is
exclusively expressed in the hepatocytes and in the tubule
epithelial cells in human kidney [5]. Thus, apoM may
have specific function in vivo, which may be related to the
hepatic lipid and/or lipoprotein metabolism.
Regulation of apoM expression
In vitro, several biological factors have been tested to
examine their influences over the transcription and secre-
tion of apoM in hepatic cell line (HepG2 cells). Like apoB,
apoM is highly hydrophobic and must co-circulate with
lipoprotein particles in the blood stream. It has been dem-
onstrated that apoB could be down-regulated by trans-
forming growth factor-beta (TGF-β) [7,8]. Xu et al
reported that TGF-β could also down-regulate apoM
expression and secretion in HepG2 cells [9]. It suggests
that apoM, similar to apoB, may involve in the hepatic
lipoprotein metabolism in vivo. In another study, Xu et al
demonstrated that platelet-activating factor (PAF) could
up-regulate apoM expression in HepG2 cells, whereas, lex-
ipafant, a PAF-receptor antagonist significantly sup-
pressed the mRNA levels and the secretion of apoM in
HepG2 cells in a dose-dependent manner. Neither tumor
necrosis factor-α (TNF-α) nor interleukin-1α (IL-1α)
influences apoM expression or secretion in HepG2 cell
cultures [10]. It indicates that apoM may relate to the host
defense response because apoM gene is located in histo-
compatibility complex III (HMC-III) region on chromo-
some 6. Many genes in this region are related to the
immune response, and the apoM gene is very close to the
TNF-α gene and lymphotoxin genes. Thus, apoM may also
be related to the immune response system, or regulated by
cytokines or other inflammatory factors.
Administration of adrenocorticotropic hormone (ACTH)
has beneficial effects on plasma lipoproteins [11-15]. A
consistent decrease of plasma total cholesterol and LDL
cholesterol by 20–40% is seen during ACTH treatment
[14-17]. It has been demonstrated that pronounced
hypolipidimic effects of ACTH might be related to the
Comparison of apoM amino acid sequence of rat, human and mouseFigure 2
Comparison of apoM amino acid sequence of rat, human and mouse. Dots indicate residues that are identical to the top line (rat). 
One potential site for N-linked glycosylation site (Asn-Glu-Thr) is indicated by a large dot above the sequence of human apoM 
(❍). Two sequences underlined indicate the typical lipocalin motifs.
ApoM-Rat MFHQVWAALL YLYGLLFNSM NQCPEHSQLM TLGMDDKETP EPHLGLWYFI AGAAPTMEEL
ApoM-Human ....I..... .F..IIL..I Y........T ...V.G..F. .V...Q.... ......K...
ApoM-Mouse .......... S......... .........T A.....T... .......... ....S.T...
ApoM-Rat ATFDQVDNIV FNMAAGSAPR QLQLRATIRT KNGVCVPRKW TYHLTEGKGN TELRTEGRPD
ApoM-Human ....P..... .........M ..H......M .D.L...... I.....--.S .D........
ApoM-Mouse ....P..... .......... .......... .S........ ..R....... M.........
ApoM-Rat MKTDLFSISC PGGIMLKETG QGYQRFLLYN RSPHPPEECV EEFQSLTSCL DFKAFLVTPR
x
ApoM-Human ...E...S.. ......N... .......... .......K.. ...K...... .S....L...
ApoM-Mouse .......S.. .......... .......... .......K.. .......... ..........
ApoM-Rat NQEACPLSSK
ApoM-Human .....E..NN
ApoM-Mouse ..........Page 3 of 5
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ever ACTH didn't influence apoM expression and secre-
tion in vivo and in vitro [18,19], indicates that apoM may
have somewhat difference from apoB on lipid and/or
lipoprotein metabolism in vivo. Richter et al. reported that
apoM gene expression could be regulated by HNF-1α.
Mutant HNF-1α-/- mice completely lack expression of
apoM in liver and kidney. Serum apoM levels in HNF-
1α+/- mice are reduced by 50% compared with wild-type
animals. By analyzing the apoM promoter and identifying
a conserved HNF-1 binding site, they showed that HNF-
1α is a potent activator of apoM promoter, that a specific
mutation in the HNF-1 binding site abolished transcrip-
tional activation of apoM gene. HNF-1α protein can bind
to the HNF-1 binding site of apoM promoter in vitro [20].
Liang and Tall reported that leptin up-regulated mRNA
level of apoM in ob/ob mice [21], suggesting that leptin
could stimulate hepatic cells to produce apoM. Faber et al.
reported that plasma concentration of apoM was similar
in wild-type, LDL receptor-deficient and apoE deficient
mice but was reduced by 33% in apoA-I-deficient mice
compared with the wide-type mice, which suggest a con-
nection between apoM and apoA-I metabolism [3]. Xu et
al., found that in both liver and kidney, expression of
apoM was significantly lower in leptin deficient ob/ob
mice and in leptin-receptor deficient db/db mice than in
control mice. Furthermore, leptin administration signifi-
cantly increased plasma apoM levels and apoM mRNA
levels in liver and in kidney in ob/ob mice [22]. It is con-
cluded that both leptin and leptin-receptor are essential
for the apoM expression, indicating that leptin is a physi-
ological regulating factor on apoM synthesis in vivo.
Physiopathology and potential clinical 
importance of apoM
Xu et al. investigated the relationship between plasma
apoM levels and leptin levels, body mass index (BMI),
fasting glucose, fasting insulin as well as lipoprotein con-
centrations in females displaying a wide range in BMI
(18.9–57.1 kg/m2, n = 51). In univariate analysis, apoM
correlated significantly to leptin (r = 0.54, P < 0.001), BMI
(r = 0.70, P < 0.001), fasting insulin (r = 0.33, P = 0.025),
total cholesterol (r = -0.41, P = 0.016), and LDL-choles-
terol (r = -0.39, P = 0.018). The correlations between
apoM and cholesterol and between apoM and leptin
remained significant after adjustment for the influence of
BMI. Forward stepwise multiple regressions when leptin,
BMI, insulin and cholesterol were entered in a model as
independent variables and apoM as the dependent varia-
ble showed that cholesterol and leptin were independent
predictors of circulating apoM. These two parameters
yielded an r2 of 0.28, thereby explaining approximately
30% of the variance in apoM. Hence, apoM is positively
correlated to leptin and negatively correlated to choles-
terol levels in humans [23]. Richter et al. measured apoM
levels in the serum of nine HNF-1α /maturity-onset diabe-
tes of the young (MODY3) patients, nine normal matched
control subjects (HNF-1α +/+), and nine HNF-4α /
MODY1 subjects. Serum levels of apoM were significantly
decreased in HNF-1α /MODY3 subjects when compared
with control subjects as well as with HNF-4α /MODY1
subjects, indicating that HNF-1α haploinsufficiency
rather than hyperglycemia is the primary cause of
decreased serum apoM protein concentrations. Thus,
serum levels of apoM may be a useful serum marker for
the identification of MODY3 patients [20]. Alzheimer's
disease (AD) is a complex, multifactor disorder, probably
resulting from an interaction between environmental and
genetic factors [24-26]. Increasing evidence points to a
link between cholesterol turnover and AD [27,28], sug-
gesting that genes implicated in brain cholesterol home-
ostasis may be potential candidate genes for AD. It is well
known that apoE genotype and apoE receptor are related
to AD [28,29]. With this background, Kabbara et al exam-
ined association of apoM with the risk of developing AD.
It is excluded apoM as a genetic determinant of AD in a
large French case control population [30].
Conclusion
In conclusion, apoM is a novel HDL apolipoprotein. Like
apoB apoM could be regulated by several cytokines in vivo
and in vitro. HNF-1α is one of the most important activa-
tor of apoM gene promoter. Plasma apoM concentration
is positively correlated to leptin levels and negatively
related to plasma cholesterol levels. Both leptin and leptin
receptor are essential for apoM expression in vivo. Plasma
apoM levels may be used as the marker for identification
of MODY3. The detailed relationship between apoM and
MODY3 as well as obese needs further investigation.
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